LLY compared with AVTX: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

AVTXAvalo Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

AVTXAvalo Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

AVTX2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±16.8%▼−6.22%×0.37

Q2 FY26±19.6%▼−0.74%×0.04

= impliedLLY realized, solidAVTX realized, hatchedOne scale, both sides: full bar = 20%× = |realized| ÷ impliedspan: LLY 267d · AVTX 91dSource: market data

LLYELI Lilly & Co

1,371.32· pre 1,350.03· delayed

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

AVTXAvalo Therapeutics, Inc.

6.64· pre 6.89· delayed

Pre-marketNov 6 '26delayed

Mkt cap$383.4MRevenue$59,000Q4 FY25Revenue—

Compare

Pre-marketNov 6 '26delayed

LLYELI Lilly & Co

AVTXAvalo Therapeutics, Inc.

1,371.32pre 1,350.03delayed

Price

6.64pre 6.89delayed

$1.2T

Mkt cap

$383.4M

Q3 FY26$24.4B

Revenue

$59,000Q4 FY25

FY25$65.2B

Revenue

—

LLY1,371.32vsAVTX6.64Pre-marketNov 6 '26delayed